ImmunityBio Shares Gain Momentum on Clinical and Financial Progress

Positive early-stage clinical data for its immunotherapy drug Anktiva, presented by the company’s founder, provided a pre-market lift to ImmunityBio shares on Friday. The update, highlighting the treatment’s potential in oncology, arrives alongside recent financial results that surpassed Wall Street’s expectations.

Financial Performance Exceeds Estimates

The biotechnology firm’s fourth-quarter 2025 results have bolstered investor confidence. ImmunityBio reported revenue of $38.29 million, exceeding analyst forecasts. The company also posted a narrower loss per share of $0.06, outperforming the anticipated loss of $0.08 and marking a clear sequential improvement. A standout figure was the 434% year-over-year growth in product revenue, indicating strong commercial traction.

Financially, the company maintains a solid position with $257.8 million in cash and equivalents, supported by prior financing activities. Investors can anticipate the next key update on May 11, 2026, when ImmunityBio is scheduled to release its first-quarter report, likely providing further details on Anktiva’s market penetration.

Should investors sell immediately? Or is it worth buying ImmunityBio?

Promising Early Clinical Signals

The recent focus has been on new analyses for Anktiva. Initial data from the first 20 treated patients demonstrated a significant immune activation, specifically evidenced by an increase in lymphocyte counts. These early findings support the ongoing Phase 2/3 studies. Within those trials, 58.2% of patients remained cancer-free after twelve months of treatment. Furthermore, long-term data indicates that over 80% of participants avoided surgical bladder removal within a three-year period.

Regulatory Advancements Support Commercial Strategy

Alongside clinical progress, ImmunityBio is advancing its global commercialization efforts. Anktiva has now been officially listed on the drug formulary for bladder cancer in Macau. A significant milestone was also achieved in the United States: the National Comprehensive Cancer Network (NCCN) updated its clinical guidelines to recommend the therapy for papillary bladder cancer. To expand the drug’s approved patient population, ImmunityBio has resubmitted a corresponding application to the U.S. Food and Drug Administration (FDA).